 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > BioTime, Inc.
 |
BioTime, Inc. |
 |
 |
 |
NEWS FROM THE STANDARD |
 |
Ex-Exec Tracker
Oct 31 2000 05:17 PM PST
Dawn of the Euro Net
Oct 20 2000 05:37 AM PDT
Portal Said to Make Play for Vibe and Spin
Sep 13 2000 12:38 PM PDT
Gates and Malone Explore Cable Hookups
Jul 24 2000 12:00 AM PDT
Retailers May Not Like Sony's New Look
Jul 17 2000 06:41 PM PDT
PROFILE |
 |
After a long day in surgery, it's BioTime. The company develops water-based solutions to prevent massive blood loss after traumatic injury, preserve organs for transplant, or replace blood during such procedures as cardiac bypass. BioTime's Hextend has received FDA approval to maintain blood volume during surgery; the company hopes to extend its use to trauma situations. The firm continues to develop PentaLyte, a short-lasting blood volume replacement, and HetaCool, intended to replace blood volume in cryosurgery and preserve donated organs. Abbott Laboratories is licensed to make and sell Hextend in the US and Canada; a unit of Akzo Nobel will sell the product outside the US, Canada, and Japan.
COMPETITION |
 |
Abbott Laboratories (ABT)
Baxter International Inc. (BAX)
E. I. du Pont de Nemours and Company (DD)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: (90.0)%
Employees: 16
Revenue per employee: $6,250.00
KEY PEOPLE |
 |
Paul Segall
CEO
Victoria Bellport
CFO
CONTACT INFO |
 |
935 Pardee St.
Berkeley, CA 94710
US
Phone: 510-845-9535
Fax: 510-845-7914
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |